Article
Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.
JAMA oncology - 1 Apr 2026
Napolitano Andrea, Joensuu Heikki, Rothschild Sara, Evans Denisse, Heinrich Michael C, Sutton Thomas L, Mayo Skye C, Boye Kjetil, Falkenhorst Johanna, Le Cesne Axel, Hohenberger Peter, Rutkowski Piotr, van Houdt Winan J, Steeghs Neeltje, Gelderblom Hans, Desar Ingrid M E, Pantaleo Maria A, Nishida Toshiro, Reichardt Peter, Blay Jean-Yves, Somaiah Neeta, Haddad Elise F Nassif, Grignani Giovanni, Baldi Giacomo G, Steigen Sonja E, Braconi Chiara, Nilsson Bengt, Singh Arun S, Fumagalli Elena, Cananzi Ferdinando C M, Italiano Antoine, Ceruso Mariella Spalato, Brunello Antonella, Magnússon Magnús K, Jonasson Jon G, Marquina Gloria, Hindi Nadia, Cirilli Claudia, Federico Massimo, Fausti Valentina, Bordoni Andrea, Sufliarsky Jozef, Mazzocca Alessandro, Martin-Broto Javier, Gronchi Alessandro, Trent Jonathan C, Casali Paolo G, Bauer Sebastian, Jones Robin L, Vincenzi Bruno
Abstract excerpt
Importance: Gastrointestinal stromal tumors (GISTs) harboring KIT exon 9 mutations represent a biologically distinct subgroup with reduced sensitivity to standard-dose imatinib in the advanced setting. The benefit of adjuvant imatinib in this population remains uncertain. Objective: To evaluate the association between adjuvant imatinib and recurrence-free survival (RFS) and overall survival (OS) in patients with...
Read the complete abstract on PubMed